This site is intended for US Healthcare Professionals Only

Important Information

Jump to section


    It is permissible for a project to receive additional funding from another source. However, this information must be provided on the full application form. The maximum amount of additional funding allowed is 100% of the value of the award, i.e. matching funding. For example, if the Bayer award is for $25,000, the recipient could receive $25,000 from another source. In the event of a change in the status of a pending application, all applicants are required to notify the Administrator.

    Applicants may request institutional overhead payments. In some instances, the Grants Review Committee may determine if or to what extent institutional overhead payments will be made in conjunction with a particular proposal. It is important to note that any institutional overhead payments will be paid out of the amount funded, not in addition to it. The maximum payment will be 20-25% of the value of the award.

    • Salary and fringe benefits
    • Equipment and supplies necessary to fulfill the project’s aims
    • Costs associated with the publication of the research.
    • Salaries, travel and/or housing related to sabbaticals
    • Purchase or rental of office equipment
    • Fees for tuition
    • Membership dues, subscriptions, books or journals.

    Projects will receive 25% of the funding total upfront (after all required documents have been received) and then per agreed milestone  (following receipt of satisfactory Project and Financial Reports).


      Applicants may only receive one Level 2 and one Level 3 Award from the program.

      Applicants who have received funding for a Level 1 or Level 4 Award must wait one year from the expiration of current funding before re-applying to this category.

      More than one application from the same institution, i.e. university, hospital, center, is permitted. However, multiple applications from researchers at such an institute collaborating on one project are not permitted.

      If there are any significant changes in an award recipient’s circumstances, the award recipient must contact the Administrator to describe these changes and explain how they might affect the use of awarded funds. Awards are made to the award recipient and the institution with which he/she is affiliated. Thus, the PHAB Administrator must be notified of any changes in institutional affiliation.

      The transfer of a grant to another institution or investigator will be at the sole discretion of the PHAB Administrator.

      Progress and Financial reports for one-year awards must be submitted to the Program Administrator  at 6 months, and Progress and Financial reports for two-year awards must be submitted at 6, 12 and 18 months. For the two-year Awards, the 6, 12, and 18-month Progress and Financial reports must be received within 30 days of the end of these periods. Final reports are due 60 days after the end of the funding period. Progress and Financial report templates will be e-mailed to awardees at least one month before these deadlines.

      The Program reserves the right to terminate support of a funded project at any time for cause.


        For-profit organizations are not allowed to apply to the PHAB Awards, e.g. pharmaceutical companies, homecare companies, health maintenance organizations, etc. The exceptions are research laboratories and academic institutions that may exist as part of a hospital that is run for profit. If in doubt about eligibility, please contact the Program  Administrator.

        As a condition of funding, Bayer may ask for a right of first refusal to obtain an exclusive worldwide license to any technology invented or improved under the grant. This intellectual property includes, but is not limited to, patented inventions, technical data, materials and know-how. It does not include any technology invented prior to the award period or after the end of the award period, or to technology invented by the investigators during the period of funding but not supported in any way by this award.

        Bayer recognizes that its conditions may prove prohibitive for certain institutions with conflicting intellectual property policies in place, and consequently it is open to alternate arrangements if necessary. Such arrangements, however, should be aligned with the PHAB’s objective of treating, to the greatest extent possible, all award recipients in a substantially identical manner.


          For applications to the Level 2, 3 and 4 categories, applicants will be required to describe how their proposed research will translate into clinical benefits for patients with pulmonary hypertension. The applications that offer the most compelling translational opportunities will be given greater weight during the review process.

          Applicants requesting an award to carry out research with recombinant molecules and/or animal or human subjects must obtain approval from the appropriate institutional or government authorities, e.g. an Institutional Review Board. If an applicant’s institution does not require special permission for using recombinant molecules, then this must be communicated to the Administrator. Bayer may provide assistance with this process if requested by the investigator.

          The Administrator  must receive copies of appropriate permissions before any award funds will be disbursed.

          The applicant’s institution has responsibility for ensuring that the rights of any human subjects are upheld and that animals are cared for in a humane manner.

          The PHAB Awards encourages award recipients to publish work carried out under an award; this includes abstract submissions to congresses. Award recipients must acknowledge the receipt of funding from the PHAB Awards in publications and abstracts describing research conducted with awards received from PHAB.

          When clinical trials are required for clinical investigation, the project must meet certain Bayer international standards for clinical studies and conform to all local safety reporting regulations.

          Patient safety is the primary concern in any clinical study, so the company will not release funds for the clinical trial until both the company and the investigators agree on the safety and suitability of the trial. In addition, relevant patient safety data must be supplied to the appropriate Bayer safety officer.